Triazole-Resistance in Environmental Aspergillus fumigatus in Latin American and African Countries
- PMID: 33921497
- PMCID: PMC8070258
- DOI: 10.3390/jof7040292
Triazole-Resistance in Environmental Aspergillus fumigatus in Latin American and African Countries
Abstract
Triazole-resistance has been reported increasingly in Aspergillus fumigatus. An international expert team proposed to avoid triazole monotherapy for the initial treatment of invasive aspergillosis in regions with >10% environmental-resistance, but this prevalence is largely unknown for most American and African countries. Here, we screened 584 environmental samples (soil) from urban and rural locations in Mexico, Paraguay, and Peru in Latin America and Benin and Nigeria in Africa for triazole-resistant A. fumigatus. Samples were screened using triazole-containing agars and confirmed as triazole-resistant by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth dilution reference method. Isolates were further characterized by cyp51A sequencing and short-tandem repeat typing. Fungicide presence in samples was likewise determined. Among A. fumigatus positive samples, triazole-resistance was detected in 6.9% (7/102) of samples in Mexico, 8.3% (3/36) in Paraguay, 9.8% (6/61) in Peru, 2.2% (1/46) in Nigeria, and none in Benin. Cyp51A gene mutations were present in most of the triazole-resistant isolates (88%; 15/17). The environmentally-associated mutations TR34/L98H and TR46/Y121F/T289A were prevalent in Mexico and Peru, and isolates harboring these mutations were closely related. For the first time, triazole-resistant A. fumigatus was found in environmental samples in Mexico, Paraguay, Peru, and Nigeria with a prevalence of 7-10% in the Latin American countries. Our findings emphasize the need to establish triazole-resistance surveillance programs in these countries.
Keywords: Africa; America; Aspergillus fumigatus; antifungal resistance; environment; epidemiology.
Conflict of interest statement
K.L. has received consultancy fees from MSD, SMB Laboratories Brussels, and Gilead; travel support from Pfizer and MSD; and speaker fees from Gilead, MSD, FUJIFILM WAKO, and Pfizer. J.M. has received research grants from Merck/MSD, Gilead Sciences, and Pfizer; is a consultant to Astellas, Basilea, Bio-Rad, Merck/MSD, Pfizer, Schering-Plough, F2G, Gilead Sciences, Cidara, Scynexis, Amplyx, and Luminex; and has served on the speaker’s bureau of Astellas, Gilead Sciences, Bio-Rad, Merck/MSD, Pfizer, Schering-Plough, Basilea, and Viropharma/Shire. P.E.V. received research grants from Gilead Sciences, Astellas, MSD, F2G, and Bio-Rad; he is a speaker for Gilead Sciences and MSD; and is on the advisory boards for Pfizer, MundiPharma, Cidara, MSD, and F2G. The remaining authors have nothing to declare.
Figures

Similar articles
-
Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014.Antimicrob Agents Chemother. 2015 Nov 2;60(1):387-92. doi: 10.1128/AAC.02326-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26525787 Free PMC article.
-
Triazole resistance in Aspergillus fumigatus isolates in Africa: a systematic review.Med Mycol. 2022 Aug 22;60(8):myac059. doi: 10.1093/mmy/myac059. Med Mycol. 2022. PMID: 35906879
-
Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait.Environ Res. 2014 Aug;133:20-6. doi: 10.1016/j.envres.2014.05.009. Epub 2014 Jun 4. Environ Res. 2014. PMID: 24906064
-
Stable prevalence of triazole-resistance in Aspergillus fumigatus complex clinical isolates in a Belgian tertiary care center from 2016 to 2020.J Infect Chemother. 2021 Dec;27(12):1774-1778. doi: 10.1016/j.jiac.2021.08.024. Epub 2021 Sep 10. J Infect Chemother. 2021. PMID: 34518094
-
Global Aspects of Triazole Resistance in Aspergillus fumigatus with Focus on Latin American Countries.J Fungi (Basel). 2017 Feb 10;3(1):5. doi: 10.3390/jof3010005. J Fungi (Basel). 2017. PMID: 29371524 Free PMC article. Review.
Cited by
-
Triazole susceptibility of Aspergillus species: environmental survey in Lagos, Nigeria and review of the rest of Africa.Ther Adv Infect Dis. 2021 Sep 12;8:20499361211044330. doi: 10.1177/20499361211044330. eCollection 2021 Jan-Dec. Ther Adv Infect Dis. 2021. PMID: 34532039 Free PMC article.
-
Selection and Amplification of Fungicide Resistance in Aspergillus fumigatus in Relation to DMI Fungicide Use in Agronomic Settings: Hotspots versus Coldspots.Microorganisms. 2021 Nov 26;9(12):2439. doi: 10.3390/microorganisms9122439. Microorganisms. 2021. PMID: 34946041 Free PMC article. Review.
-
Aspergillus Species Causing Invasive Fungal Disease in Queensland, Australia.Mycopathologia. 2023 Jun;188(3):211-219. doi: 10.1007/s11046-023-00713-5. Epub 2023 Apr 17. Mycopathologia. 2023. PMID: 37067664 Free PMC article.
-
Fungicide effects on human fungal pathogens: Cross-resistance to medical drugs and beyond.PLoS Pathog. 2021 Dec 9;17(12):e1010073. doi: 10.1371/journal.ppat.1010073. eCollection 2021 Dec. PLoS Pathog. 2021. PMID: 34882756 Free PMC article. Review.
-
Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.Euro Surveill. 2025 May;30(18):2400559. doi: 10.2807/1560-7917.ES.2025.30.18.2400559. Euro Surveill. 2025. PMID: 40341104 Free PMC article.
References
-
- Schauwvlieghe A.F.A.D., Rijnders B.J.A., Philips N., Verwijs R., Vanderbeke L., Van Tienen C., Lagrou K., Verweij P.E., Van De Veerdonk F.L., Gommers D., et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir. Med. 2018;6:782–792. doi: 10.1016/S2213-2600(18)30274-1. - DOI - PubMed
-
- Patterson T.F., Thompson G.R., Denning D.W., Fishman J.A., Hadley S., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Nguyen M.H., et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016;63:e1–e60. doi: 10.1093/cid/ciw326. - DOI - PMC - PubMed
-
- Ullmann A., Aguado J., Arikan-Akdagli S., Denning D., Groll A., Lagrou K., Lass-Flörl C., Lewis R., Munoz P., Verweij P., et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 2018;24:e1–e38. doi: 10.1016/j.cmi.2018.01.002. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources